TY - JOUR
T1 - Comparison of Tc-99m DTPA aerosol ventilation studies with pulmonary function testing in cystic fibrosis
AU - Kuni, C. C.
AU - Budd, J. R.
AU - Regelmann, W. E.
AU - Ducret, R. P.
AU - Boudreau, R. J.
PY - 1993/3/8
Y1 - 1993/3/8
N2 - In 43 patients with cystic fibrosis, the results of 122 Tc-99m DTPA aerosol ventilation (DAV) studies were compared with pulmonary function tests (PFTs) that were performed within 24 hours of the DAV studies. The DAV studies were evaluated blindly for (A) number of pulmonary segments showing little or no ventilation, (B) number of foci of bronchial deposition of aerosol, and (C) subjective overall improvement, lack of change, or worsening from the previous study. (A) and (B) correlated significantly with all PFTs (p's <.001, r's = -.51 to -.73). Changes in (A) and (B) also correlated with changes in PFTs (p's ≤.001, r's = -.37 to -.58). The three populations in (C) were significantly different from each other with respect to changes in all PFTs (p ≤.002). Intervals between studies showing subjective improvement, no change, and worsening averaged 60, 133, and 306 days, respectively. These results suggest that DAV is an indicator of both regional and global pulmonary function and may be useful in evaluating patients with cystic fibrosis.
AB - In 43 patients with cystic fibrosis, the results of 122 Tc-99m DTPA aerosol ventilation (DAV) studies were compared with pulmonary function tests (PFTs) that were performed within 24 hours of the DAV studies. The DAV studies were evaluated blindly for (A) number of pulmonary segments showing little or no ventilation, (B) number of foci of bronchial deposition of aerosol, and (C) subjective overall improvement, lack of change, or worsening from the previous study. (A) and (B) correlated significantly with all PFTs (p's <.001, r's = -.51 to -.73). Changes in (A) and (B) also correlated with changes in PFTs (p's ≤.001, r's = -.37 to -.58). The three populations in (C) were significantly different from each other with respect to changes in all PFTs (p ≤.002). Intervals between studies showing subjective improvement, no change, and worsening averaged 60, 133, and 306 days, respectively. These results suggest that DAV is an indicator of both regional and global pulmonary function and may be useful in evaluating patients with cystic fibrosis.
UR - http://www.scopus.com/inward/record.url?scp=0027474854&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027474854&partnerID=8YFLogxK
U2 - 10.1097/00003072-199301000-00004
DO - 10.1097/00003072-199301000-00004
M3 - Article
C2 - 8422713
AN - SCOPUS:0027474854
SN - 0363-9762
VL - 18
SP - 15
EP - 18
JO - Clinical Nuclear Medicine
JF - Clinical Nuclear Medicine
IS - 1
ER -